伊立替康联合顺铂同步放化疗治疗中晚期宫颈癌的疗效对照研究-论文.pdf

《伊立替康联合顺铂同步放化疗治疗中晚期宫颈癌的疗效对照研究-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、J实1用ofC临'lln焉l医药鸯i志2～01⋯3年第⋯1⋯7卷第21期·aan122·ouma．ofClinicaMedicinenPractice伊立替康联合顺铂同步放化疗治疗中晚期宫颈癌的疗效对照研究赵林，张春林(甘肃省肿瘤医院，甘肃兰州，730050)摘要：目的探讨伊立替康联合顺铂同步放化疗治疗1Ib～IVa期宫颈癌的安全性和有效性。方法将64例中晚期宫颈癌患者随机分为对照组和实验组，每组32例。对照组给予常规放射治疗，实验组在此基础上再给予伊立替康颐铂同步化疗。比较2组的肿瘤控制或消退、肿瘤细胞增殖或凋亡情况以及毒副作用。结果实验组的局部控制率

2、为84．38％，明显高于对照组的62．50％(P<0．05)；实验组肿瘤体积肖退50％所需的时问(T50)为(10．41±3．05)d，明显短于对照组的(14．85±3．20)d(P<005)；实验组治疗后的PCNA水平明显低于对照组(P<0．05)；实验组治疗后的A—LI水平明显高于对照组(P

3、中图分类号：R737．33文献标志码：A文章编号：1672—2353(2013)21—122—03DOI：10．7619／jcmp．201321036Comparativestudy0nradiotherapybetweenirinotecanandcisplatinconcurrentchemotherapyfor64patientswithadvancedcervicalcancerZHAOLin，ZHANGChunlin(GansuTumorHospital，LanfzJzou，Gansu，730050)ABSTRACT：ObjectiveToin

4、vestigatethesafetyandeffectivenessofirinotecanandcisplatinconcurrentchemotherapyinthetreatmentofadvancedcervicalcancer．MethodsSixty—fourpa—tientswererandomlydividedintotwogroups．Thecontrolgroup(=32)wastreatedwithconven—tionalradiotherapy，andtheexperimentalgroup(／7=32)wasgivenirin

5、otecan／cisplatinconcurrentchemotherapy．Thetumorcontrolorregression，tumorceltproliferationorapoptosis，andadversereactionsintwogroupswereobservedandcompared．ResultsThetotaltumorcontrolratewas84．38％intheexperimentalgroup．thetotaltunlorcontrolratewas62．50％inthecontrolgroup，SOtheexper

6、imentalgroupwassignificantlyhigherthanthecontrolgroup(P<0．05)．T50(10．41±3．05)dintheexperimentalgroupwassignificantlyshorterthanthecontrolgroup(14．85±3．20)d(P<0．05)．ThePCNAaftertreatmentintheexperinmnta[groupwaslowerthanthecontrolgroup，andtheA—LIaftertreatmentintheexperimentalgrou

7、pwashigherthanthecontro1group(P<0．05)．Theadversereactionsincidenceofdelayeddiarrhea，nausea，vomiting，intheexperi—mentalgroupwashigherthanthecontrolgroup(P<0．05)，andotheradversereactionsintwogroupsshowednosignificantdifference．ConclusionIrinotecan／cisplatinconcurrentchemotherapyint

8、hetreatmentofadvancedcervicalcancercanim